TherapeuticsMD Announces $50,000,000 Proposed Public Offering of Common Stock

  TherapeuticsMD Announces $50,000,000 Proposed Public Offering of Common

Business Wire

BOCA RATON, Fla. -- March 7, 2013

TherapeuticsMD, Inc. (OTCQB: TXMD) today announced that it intends to offer
and sell, subject to market and other conditions, $50,000,000 of its common
stock in an underwritten public offering. There can be no assurance as to
whether or when the offering may be completed, or as to the actual size or
terms of the offering.

Jefferies LLC is acting as sole book-running manager for the offering, and
Noble Financial Capital Markets is acting as co-manager for the offering.

A shelf registration statement relating to the public offering of the shares
of common stock described above was filed with the Securities and Exchange
Commission (SEC) and is effective. A preliminary prospectus supplement related
to the offering will be filed with the SEC and will be available on the SEC’s
website located at Copies of the preliminary prospectus
supplement and the accompanying prospectus relating to this offering, when
available, may be obtained from Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by
telephone at (877) 547-6340, or by e-mail at

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation, or sale is not permitted. Any offer, if at all, will be made
only by means of a prospectus, including a prospectus supplement, forming part
of the effective shelf registration statement.

About TherapeuticsMD

TherapeuticsMD, Inc. is a women’s healthcare product company focused on
creating and commercializing products targeted exclusively for women. The
Company currently manufactures and distributes branded and generic
prescription prenatal vitamins as well as over-the-counter vitamins and
cosmetics. The Company is currently focused on conducting the clinical trials
necessary for regulatory approval and commercialization of advanced hormone
therapy pharmaceutical products designed to alleviate the symptoms of and
reduce the health risks resulting from menopause-related hormone deficiencies.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth
in this press release, including statements regarding TherapeuticsMD’s
expectations with respect to the completion, timing and size of its proposed
offering, are forward-looking statements within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to risks and uncertainties that
may cause actual results to differ materially, including the risks and
uncertainties associated with market conditions, the satisfaction of customary
closing conditions related to the proposed offering, risks and uncertainties
associated with TherapeuticsMD’s business and finances in general, and other
risks detailed in TherapeuticsMD’s annual report on Form 10-K filed with the
SEC on March 27, 2012, current report on Form 8-K filed with the SEC on
January 25, 2013, and other filings with the SEC. These forward-looking
statements are based on current information that may change and you are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. All forward-looking
statements are qualified in their entirety by this cautionary statement, and
TherapeuticsMD undertakes no obligation to revise or update any
forward-looking statement to reflect events or circumstances after the
issuance of this press release.


TherapeuticsMD, Inc.
Daniel A. Cartwright, 561-961-1911
Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.